ES2163543T3 - Metodo para inhibir los efectos inducidos por endotoxinas. - Google Patents

Metodo para inhibir los efectos inducidos por endotoxinas.

Info

Publication number
ES2163543T3
ES2163543T3 ES96104316T ES96104316T ES2163543T3 ES 2163543 T3 ES2163543 T3 ES 2163543T3 ES 96104316 T ES96104316 T ES 96104316T ES 96104316 T ES96104316 T ES 96104316T ES 2163543 T3 ES2163543 T3 ES 2163543T3
Authority
ES
Spain
Prior art keywords
endotoxins
sub
effects induced
inhibiting
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96104316T
Other languages
English (en)
Spanish (es)
Inventor
Christer Grimfors
Ellinor Lampen
Svante Lindgren
Goran Sandberg
Raymond Wahlen
Bjorn Westberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Application granted granted Critical
Publication of ES2163543T3 publication Critical patent/ES2163543T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ES96104316T 1991-01-09 1991-12-20 Metodo para inhibir los efectos inducidos por endotoxinas. Expired - Lifetime ES2163543T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100059A SE468881B (sv) 1991-01-09 1991-01-09 Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar

Publications (1)

Publication Number Publication Date
ES2163543T3 true ES2163543T3 (es) 2002-02-01

Family

ID=20381566

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96104316T Expired - Lifetime ES2163543T3 (es) 1991-01-09 1991-12-20 Metodo para inhibir los efectos inducidos por endotoxinas.
ES92903332T Expired - Lifetime ES2109338T3 (es) 1991-01-09 1991-12-20 Metodo para separar endotoxinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES92903332T Expired - Lifetime ES2109338T3 (es) 1991-01-09 1991-12-20 Metodo para separar endotoxinas.

Country Status (11)

Country Link
EP (4) EP0719550B1 (enExample)
JP (1) JP3200604B2 (enExample)
AT (2) ATE204753T1 (enExample)
AU (1) AU9152891A (enExample)
DE (2) DE69223426T2 (enExample)
DK (2) DK0719550T3 (enExample)
ES (2) ES2163543T3 (enExample)
GR (1) GR3025573T3 (enExample)
PT (1) PT715849E (enExample)
SE (1) SE468881B (enExample)
WO (1) WO1992011847A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436270A (en) * 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
EP0738146B1 (en) * 1994-01-11 2003-05-02 N.V. Nutricia Method of treating disorders of the animal or human body by administering amino acids
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
ATE279919T1 (de) * 1997-08-15 2004-11-15 Carolyn Ann Fairbanks Agmatin für die behandlung neuropathischer schmerzen
US6774102B1 (en) 1999-09-29 2004-08-10 Gambro Dialysatoren Gmbh & Co. Kg Extracorporeal endotoxin removal method
NZ532217A (en) 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
SE526038C2 (sv) * 2002-07-08 2005-06-21 Gambro Lundia Ab Polymeraffinitetsmatris, förfarande för framställning därav och anvädning därav
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
EP1732383A4 (en) 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH RECOMBINANT ADENO ASSOCIATED VIRUS VECTORS THAT CODE APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
EP2386861A3 (en) 2005-07-13 2012-07-18 Crossbeta Biosciences B.V. Cross-ß structure binding compounds
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US9375499B2 (en) 2006-07-14 2016-06-28 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA939265A (en) * 1967-11-18 1974-01-01 Yoshitaka Ikezuki Injectable compositions for alleviating the pain incurred from administrations of injections
IT1127322B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici
IT1127321B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizione farmaceutiche aventi specifiche proprieta' terapeutiche nei confronti dell'edema polmonare acuto,di alcuni stati di shock e dell'iperfibrinolisi
JPH01238534A (ja) * 1988-03-17 1989-09-22 Mitsui Toatsu Chem Inc エンドトキシンの除去方法
US5019558A (en) * 1988-05-09 1991-05-28 Georges Cehovic Method for treating memory disturbances using arginine aspartate
GB8929076D0 (en) * 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation

Also Published As

Publication number Publication date
EP0566644A1 (en) 1993-10-27
EP0719550A3 (enExample) 1996-07-24
DE69223426D1 (de) 1998-01-15
ES2109338T3 (es) 1998-01-16
SE468881B (sv) 1993-04-05
GR3025573T3 (en) 1998-03-31
ATE157866T1 (de) 1997-09-15
EP0719550A2 (en) 1996-07-03
DK0719550T3 (da) 2001-12-10
EP0566644B1 (en) 1997-09-10
JPH06504058A (ja) 1994-05-12
SE9100059L (sv) 1992-07-10
DE69223426T2 (de) 1998-03-12
EP0715849B1 (en) 2001-07-25
PT715849E (pt) 2002-01-30
JP3200604B2 (ja) 2001-08-20
EP0494848A1 (en) 1992-07-15
ATE204753T1 (de) 2001-09-15
EP0715849A1 (en) 1996-06-12
AU9152891A (en) 1992-08-17
EP0719550B1 (en) 2001-08-29
DK0566644T3 (da) 1998-04-27
SE9100059D0 (sv) 1991-01-09
DE69132710T2 (de) 2002-04-18
EP0494848B1 (en) 1997-03-26
DE69132710D1 (de) 2001-10-04
WO1992011847A1 (en) 1992-07-23

Similar Documents

Publication Publication Date Title
ES2113867T3 (es) Imino-derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
KR950000676A (ko) 신규 설포닐아미노 피리미딘
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
ES2157929T3 (es) Beta-d-dioxolano-nucleosidos enantiomeramente puros.
ES507394A0 (es) Mejoras en el objeto de la patente de invencion n.487.721 por procedimiento de preparacion de nuevos derivados del nortropano.
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
ES2059491T3 (es) Derivados de indol con anillos condensados.
AR032556A1 (es) Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
ES2095976T3 (es) Compuestos de pirazolopiridina y procedimiento para su preparacion.
UY27244A1 (es) Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
RU2001101556A (ru) Антитромботические соединения
ES2038074B1 (es) Procedimiento para la preparacion de nuevos derivados de benzimidazol.
ES2111163T3 (es) Uso de fosfonatos para el tratamiento de la osteoporosis.
AR129965A1 (es) Compuestos de imidazopiridina, preparación de los mismos y usos terapéuticos de los mismos
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
ATE143025T1 (de) Antivirale verbindungen
ES8606297A1 (es) Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil)-oxialquilamidas
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
ES2102870T3 (es) Benzopiranos y composiciones farmaceuticas que los contienen.
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
ES2081097T3 (es) Vacuna contra los nematodos.
ES2038163T3 (es) Procedimiento para preparar 1,3-dioxolanos trisustituidos en 2,4,4 y tetrasustituidos en 2,2,4,4.
ES2043515A1 (es) Procedimiento para la preparacion de nuevos derivados de 1-difenilmetilpiperazina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 719550

Country of ref document: ES